<DOC>
	<DOCNO>NCT00209534</DOCNO>
	<brief_summary>This study design assess safety efficacy AQUAVAN® Injection provide adequate sedation patient undergoing colonoscopy . Prior procedure , patient receive fentanyl citrate pain management follow five minute later AQUAVAN® Injection sedation . Throughout procedure , study personnel assess patient 's vital sign depth sedation . After procedure , patient , physician , evaluator ask complete satisfaction survey .</brief_summary>
	<brief_title>A Study AQUAVAN® Injection Presence Pre-Medication Patients Undergoing Elective Colonoscopy</brief_title>
	<detailed_description>Randomized , open label , multi-center , adaptive dose range study , several dose level AQUAVAN® Injection fentanyl citrate injection investigate produce desire sedation level patient undergo elective colonoscopy . A desired sedative dose/dose range dose paradigm identify base pre-set criterion use Modified Observer 's Assessment Alertness/Sedation ( OAA/S ) . The desired sedative dose/dose range dose paradigm AQUAVAN® Injection define one consistently provide mild moderate sedation ( Modified OAA/S 2 4 inclusive ) majority patient pre-medicated fentanyl citrate injection .</detailed_description>
	<mesh_term>Fospropofol</mesh_term>
	<criteria>1 . Patients provide write informed consent receive full explanation extent nature study . 2 . Patients &gt; =18 year age ≤60 year ( subset 50 patient &gt; 60 year &lt; 85 year age allow ) . 3 . Patients , female , surgically sterile , postmenopausal nonpregnant use acceptable method birth control least 1 month prior dose , negative urine pregnancy test result screen predose . 4 . Body mass index ( BMI ) 20 28 . 5 . Body weight 50 kg 100 kg . 6 . Patients ASA Physical Classification System status I II ; 7 . Patients require elective colonoscopy procedure anticipate perform &lt; 60 minute ( i.e. , procedure predict uncomplicated ) ; desire sedation colonoscopy procedure ; determine Investigator physically capable maintain adequate airway mildtomoderate sedation . 1 . Patients ingested benzodiazepine barbiturate within 14 day study start , exception phenobarbital , require 21day washout . 2 . Patients ingested opioids within 72 hour study start . 3 . Patients current symptom upper respiratory infection . 4 . Patients history allergic reaction hypersensitivity anesthetic agent , narcotic , benzodiazepine . 5 . Patients current sign significant hiatal hernia , esophageal reflux , heartburn , opinion Investigator , could interfere maintenance adequate airway . 6 . Patients history alcohol drug abuse within past 12 month ; 7 . Patients ingested alcohol caffeine within 12 hour prior admission study . 8 . Patients participate investigational drug study within 1 month prior study start . 9 . Patients unwilling adhere preprocedural postprocedural instruction . 10 . Patients donate &gt; 300 mL blood within 1 month prior study start ; 11 . Patients expose AQUAVAN previous clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>